Becalim 100mg Enlie Pharma treatment for hypercholesterol blood cholesterol (3 blisters x 10 tablets)

Pharmacological group: Lipid medication (fibrat).

Ciprofibrat is a phenoxyisobutyric derivative that has the effect of lowering blood lipid. The drug is effective in reducing both LDL and VLDL, and thus lowering blood cholesterol and lowering blood triglycerides and lipoprotein ratio. Ciprofibrat also increases HDL cholesterol.

Ciprofibrat is effective in the treatment of hyperlipidemia and increases the level of LDL and VLDL plasma (classification IIA, IIB, III and IV according to Fredrickson).

There is also evidence that Ciprofibrat reduces the frequency of coronary artery disease but does not reduce the causes of death in primary and secondary prevention of cardiovascular disease.

Dynamic pharmacokinetics

ciprofibrat is absorbed in the human body with the highest plasma concentration achieved from one to four hours after drinking. Research on the use of drugs on volunteers shows that, after 1 dose of 100 mg, the peak concentration in the blood is from 21-36 Ug/ ml. In case of regular use, this value is from 53-165 Ug/ ml.

The last half -life of the drug in the patient for long -term treatment varies from 38 to 86 hours. Patients with renal function weakened the average level of selling time increased slightly compared to normal objects (116.7 hours compared to 81.1 hours). But in patients with severe renal impairment, the selling time increased significantly (about 171.9 hours).

Be cautious when using

Need to warn patients immediately in information to health workers if there is muscle pain, muscle weakness does not explain the cause. CPK (Creatin Phosphokinase) should be evaluated right in patients with these symptoms.

Stop treatment if the muscle disease is diagnosed or if the CPK increases significantly (an increase of 5 times compared to normal level).

The dose of 200 mg of ciprofibrat daily or higher leads to an increased risk of muscle pattern. Therefore daily dose should not exceed 100 mg of ciprofibrat.

The risk of muscle disease increases if the patient is at risk of the following diseases:

Like other fibrats, the risk of muscle and myoglobin - urinary can increase when Ciprofibrat is used in combination with other fibrats or HMG enzyme inhibitors HMG COA Reductase (see the contraindications and drug interactions).

Use cautiously in patients with impaired liver function.

Should test liver function regularly (every 3 months in the first 12 months of treatment). Ciprofibrat treatment should be stopped in the case of AST and ALT increasing 3 times higher than the upper limit of normal people or when there is evidence of cholest liver damage.

The secondary cause of fat metabolism disorders, such as thyroid disorders, should be excluded or adjusted before starting lipid lowering drugs.

When used with anticoagulants, the dose of this drug should be calibrated according to the INR (see the drug interaction).

If after a few months of taking the drug, serum lipid concentration does not decrease as expected, should consider additional treatments or other treatments.

Patients with rare genetics about non -Galactose, Lapp Lactase deficiency, or Glucose - Galactose should not take this drug.

The effect of the drug on the ability to drive and operate machinery

rarely appear dizzy, drowsiness or fatigue when using Ciprofibrat. Patients should be warned if affected and should not drive or operate the machine in this case.

Use drugs for women during pregnancy and lactation

pregnancy:

There is not enough evidence of the effect of ciprofibrat on pregnant women, so the risks have not been identified. However, at high doses, teratogenic drugs on animals, thus contraindicated for pregnant women.

breastfeeding period:

There is no information on the distribution of ciprofibrat into breast milk, but the drug through mouse milk is breastfeeding, so contraindicated Ciprofibrat for women who are breastfeeding.

Drug interaction

combined with contraindications:

Combined with other fibrats: When used with other fibrats, the drug may increase the risk of muscle pattern and myoglobin - urinary.

There is no recommendation:

HMG inhibitors HMG Coa Reductase: Like other fibrats, the risk of muscle, muscle and myoglobin - urinary diseases can be increased when Ciprofibrat is used in combination with HMG COA Reductase inhibitors (see the warning and cautious part when taking the drug). Only combine if the benefits are superior to the risk. The doctor intends to use a combination of ciprofibrat with HMG enzyme inhibitors HMG Coa Reductase should refer to the product summary (SPC) of the HMG enzyme inhibitors HMG Coa Reductase corresponding to the high doses of these drugs that are contraindicated/not recommended for fibrat.

Precautions when combined:

Oral anticoagulant therapy: Ciprofibrat is a large -sized drug with protein and so it is possible to replace other drugs at the location of plasma proteins. This can increase the effects of drugs such as phenytoin, tolbutamid, other sulphonylurea derivatives and anticoagulants like Coumarin. When used in the same fibrat, the dose of anticoagulants should be reduced or calibrated according to Inr (see the warning and caution when taking the drug).

Consider when combining:

Cholestyramin and Colestipol may cause a reduction in Ciprofibrat absorption. These drugs should not be used together or close together.

estrogens: estrogens may increase lipid levels.